Global Pharmatech (GBLP) Stock Analysis & Winston Score
Global Pharmatech, Inc. is a small specialty and generic drug manufacturer in the healthcare sector. The company develops and produces pharmaceutical products, likely including generic versions of established medications sold to hospitals, pharmacies, and healthcare distributors. It operates in a crowded industry where many companies compete to supply affordable medicines to patients and healthcare systems. The company earns revenue primarily through the sale of its drug products, with a gross margin of around 25%, which is modest for the pharmaceutical industry. Its 26% return on invested capital suggests it deploys its resources reasonably efficiently relative to its small size. Generic drug manufacturers face ongoing pricing pressure as competitors enter the market with similar products, which can squeeze profits over time. The main risk for a company this size is its limited scale, which makes it harder to absorb regulatory costs, fund new drug development, or compete against larger manufacturers with broader product lines.
Winston Score: 32/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Good (15/30)
- Growth: Mixed (5/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.08
Market Cap: $33M
Sector: Healthcare
Industry: Medical - Pharmaceuticals

